Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24919553 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL24919562 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL26426519 | 0.88 | KDM4E (0.38) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL12981135 | 0.86 | TSHR (0.42) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL18649118 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL20623023 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ATSHRGAA | |
| SCHEMBL12391966 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL24966302 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL21099929 | 0.83 | KMT2A (0.39) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL18472627 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031576-A1 | RADIOLABELLED TARGETING LIGANDS | Clarity Pharmaceuticals Ltd (AU) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031576-A1 | RADIOLABELLED TARGETING LIGANDS | FOLH1, CXCR3, ACKR3 | KDM4E 2796/4885ALDH1A1 3160/4885CA12 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.